EN DE
Watch Biocon Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biocon Limited (BIOCON) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Biocon Limited stock ₹48.48, price ₹369, that is 86.8% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE376G01013

BL Biocon Limited logo Thin data Nov 7, 2026

Biocon Limited

BIOCON · NSE
Very expensive, weak quality

Our calculation puts a fair price 87% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +18.8 %/yr in INR)
Thin margins · 2.6% net margin (TTM)
0.1% dividend yield · Token dividend
Mixed vs. peers (6/13)
Costs 123 times its yearly profit.
Fair value ₹48.48 · Strongly overvalued
Quality 30/100
Negative free cash flow
Narrow moat 25/100
Thin data
Extreme value⚠ Dilution

Risks from the AI analysis

🚩Heavy US revenue dependence🚩Biosimilar price pressure from rivals🚩Gene therapy could displace biosimilars
Watch Biocon Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹440.70 ₹196.78 Fair Value ₹48.48 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ₹196.78 – ₹440.70 · fair‑value band ₹33.93 – ₹67.92 · the ₹368.50 price screens above the ₹48.48 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Biocon in your weekly email

Every Wednesday you see whether Biocon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments.

Show moreShow less

The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept.

It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies.

In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services.

Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Stock analysis

Biocon Limited (BIOCON) currently trades at ₹368.50, while our model-based Fair Value estimate is ₹48.48, 87% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of ₹75.73 per share, and 0 of the 16 models we run sit above the ₹368.50 price.

Bear case: the Dividend Discount group reads lowest at ₹7.56, and 16 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹33.93 (bear) to ₹67.92 (bull), the price of ₹368.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Biocon Limited reported revenue of ₹169B in FY2026 versus ₹81.8B in FY2022, a compound +19.9%/yr. Reported net income was ₹3.9B in FY2026, compounding −12.2%/yr from FY2022.

Key figures

Market cap ₹604B (≈ $6.4B) Mid · P/E ratio 123.7 · P/S ratio 3.45 · EPS (TTM) ₹2.98 · Dividend yield 0.1% · Net margin 2.6% · Return on equity 1.0% · Return on assets (EBIT) 7.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 16% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −87%, BIOCON screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (₹7.20 to ₹220.63). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹33.93 Fair Value ₹48.48 Bull ₹67.92
Price ₹368.50 · Downside -86.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹1.52 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹115.75 ₹121.67 ₹134.24 76
EPV ₹20.57 ₹29.79 ₹37.49 73
ROIC Compounder ₹20.57 ₹29.79 ₹37.49 72
All 16 models by family
Earnings-Based
Graham-Dodd ₹16.01 ₹93.83 ₹130.63 63
Lynch FV ₹26.58 ₹37.98 ₹49.37 61
PEG = 1.0 ₹26.58 ₹37.98 ₹49.37 57
EPV ₹20.57 ₹29.79 ₹37.49 73
Dividend Discount
Gordon GGM ₹4.36 ₹7.92 ₹10.98 68
DDM Multi-Stage ₹4.36 ₹7.20 ₹8.45 67
Multiples
P/E Multiple ₹38.85 ₹51.80 ₹64.75 63
P/S Multiple ₹30.02 ₹40.03 ₹50.03 58
P/B Multiple ₹107.63 ₹143.50 ₹179.38 55
EV/EBIT ₹41.93 ₹80.82 ₹119.71 63
EV/EBITDA ₹146.79 ₹220.63 ₹294.47 66
EV/Revenue ₹8.53 ₹44.21 ₹79.90 48
Asset-Based
NCAV (Graham) ₹15.94 ₹21.37 ₹31.89 54
Economic Profit
Residual Income ₹115.75 ₹121.67 ₹134.24 76
ROIC Compounder ₹20.57 ₹29.79 ₹37.49 72
Growth Earnings
Growth-Adj P/E ₹39.92 ₹57.03 ₹74.13 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 38
Are margins and returns getting better?
Cashflow 36
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 39
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 28
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 34
Distance to the 52-week high, does not count
New shares 18
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
Start year 2021 (pandemic). Over 10 years: +17.6% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−14.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.5%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.5% vs −5.9%, slowing
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 9%
Pace: the 5-year rate starts in 2021 (pandemic)

BIOCON screens overvalued: fair value 87% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Biocon Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −86.7% · Bottom 25%
Profitability
Return on equity (12 months) 1.0% · Above median
Return on assets 0.6% · Above median
Net margin (12 months) 2.6% · Below median
Operating margin (12 months) 6.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 3.0% · Above median
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.32× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 123.7× · Priciest 25%
P/B 1.76× · Cheaper than median
P/S (12 months) 3.45× · Cheaper than median
EV/EBITDA 19.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)15 · sector 0
PAST (return on equity)4 · sector 0
HEALTH (low debt)84 · sector 97
DIVIDEND (yield)3 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs BIOCON
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs BIOCON
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs BIOCON
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs BIOCON
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs BIOCON
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs BIOCON
argenx SE ARGX $927.21 $908.40 −2% vs BIOCON
CSL Limited CSL A$200.77 A$183.04 −9% vs BIOCON
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs BIOCON
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs BIOCON

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biocon Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Biocon Limited Fair Value". https://www.fairvalue-calculator.com/stock/BIOCON

Frequently asked questions

Is Biocon Limited (BIOCON) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ₹48.48 versus a price of ₹368.50, about 87% lower (overvalued).
What is the fair value of BIOCON?
Our model-based fair value for Biocon Limited is ₹48.48 (as of Nov 7, 2026), built from audited fundamentals. The current price: ₹368.50.
What is the quality score of BIOCON?
Biocon Limited has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biocon Limited (BIOCON)?
Our model-based price target is the fair value of ₹48.48 (as of Nov 7, 2026) from 16 valuation models. Cautious scenario ₹33.93, optimistic scenario ₹67.92. It is a calculation from audited fundamentals, not an analyst target.
What is the Biocon Limited stock forecast for 2026?
Our models put fair value at ₹48.48, about 87% lower versus a price of ₹368.50 (overvalued). Cautious scenario ₹33.93, optimistic scenario ₹67.92. The calculation is refreshed regularly with new filings.
What is the revenue of Biocon Limited (BIOCON)?
Biocon Limited reported trailing-twelve-month revenue of about ₹173B (latest available figure, as of Nov 7, 2026).
Does Biocon Limited pay a dividend?
Biocon Limited currently shows a dividend yield of 0.14% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Biocon Limited (BIOCON) and when is the ex-dividend date?
Biocon Limited pays a dividend of ₹0.5 per share a year, a dividend yield of 0.1%. The last ex-dividend date was Jul 3, 2026. A dividend has been paid every year since 2022. The payout ratio is 16.8% of earnings. Our assessment: Token dividend. At a yield of 0.1% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.1% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Biocon Limited (BIOCON)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biocon Limited it is ₹48.48 per share (as of Nov 7, 2026), against a price of ₹368.50. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Biocon Limited stock overvalued or undervalued in 2026?
As of Nov 7, 2026, BIOCON trades above its calculated fair value: price ₹368.50, fair value ₹48.48, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOCON?
No. The price is what the market pays today (₹368.50); the fair value is what the company's own numbers justify (₹48.48). For Biocon Limited the two are ₹320.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biocon Limited worth?
The market values Biocon Limited at about ₹604B (market capitalisation, as of Nov 7, 2026). Per share that is ₹368.50; our models calculate a fair value of ₹48.48 per share.
What do the bullish and bearish scenarios say about BIOCON?
Our models span a range for Biocon Limited: cautious scenario ₹33.93, base ₹48.48, optimistic ₹67.92 per share (as of Nov 7, 2026, price ₹368.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIOCON?
Biocon Limited trades at a price-to-earnings ratio of 123.7 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹48.48 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2020 to 2026), reported earnings: 53.2. Other multiples: P/B 1.8, P/S 3.5, EV/EBITDA 19.1.
How solid is the balance sheet of Biocon Limited (BIOCON)?
Balance-sheet figures for Biocon Limited (as of Nov 7, 2026): return on equity 1.0%, debt of 0.32 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is BIOCON from its 52-week high?
Biocon Limited trades at ₹368.50, about 16% below its 52-week high of ₹440.70 and 14% above the low of ₹323.50 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹48.48 is for.
Which stocks are comparable to Biocon Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biocon Limited stock attractive at the current price?
The data as of Nov 7, 2026: price ₹368.50, calculated fair value ₹48.48 (−87%), Quality Score 30/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOCON calculated?
We run Biocon Limited through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹48.48 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Biocon Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biocon Limited (BIOCON)?
The closing price on Nov 9, 2026 was ₹368.50. Our model-based fair value is ₹48.48, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biocon Limited right now?
The price sits above even our optimistic bull case (₹67.92). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹33.93 to ₹67.92) leaves room in how you read the outcome.
Where does the earnings growth of Biocon Limited (BIOCON) come from?
Earnings per share at Biocon Limited grew +1.5 % a year from 2015 to 2026. Broken into its drivers: revenue per share +17.6 %, EBIT margin −3.1 %, tax rate −1.0 %, residual (interest, one-offs) −10.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Biocon Limited

How large is the market capitalisation of Biocon Limited (BIOCON)?
The market capitalisation of Biocon Limited is ₹604B (≈ $6.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biocon Limited (BIOCON)?
The price-to-sales ratio of Biocon Limited is 3.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biocon Limited (BIOCON)?
Earnings per share at Biocon Limited are ₹2.98 (price ÷ EPS = P/E 123.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Biocon Limited (BIOCON)?
The dividend yield of Biocon Limited is 0.1% (payout 16.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Biocon Limited (BIOCON)?
The net margin of Biocon Limited is 2.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biocon Limited (BIOCON)?
The return on equity (ROE) of Biocon Limited is 1.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biocon Limited (BIOCON)?
On an EBIT basis the return on assets of Biocon Limited is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biocon Limited (BIOCON)?
The operating margin of Biocon Limited is 6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biocon Limited (BIOCON)?
Revenue at Biocon Limited is growing +3.0% versus a year earlier (3y avg +14.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biocon Limited (BIOCON)?
Earnings per share at Biocon Limited are growing −61.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biocon Limited (BIOCON) generate?
The free cash flow of Biocon Limited is −₹5.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biocon Limited (BIOCON) carry?
The net debt of Biocon Limited is ₹122B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Biocon Limited in the live analysis

One click puts Biocon Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.